Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals, adding worldwide rights to investigational gildeuretinol acetate (ALK-001) for Stargardt disease.